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Abstract 27 
Citrinin (CIT) is a nephrotoxic mycotoxin produced by Penicillium, Monascus, and 28 
Aspergillus species. CIT appears as a contaminant in cereals, cereal-based products, fruits, 29 
nuts, and spices. During the biotransformation of CIT, its major urinary metabolite 30 
dihydrocitrinone (DHC) is formed. Albumin interacts with several compounds (including 31 
mycotoxins) affecting their tissue distribution and elimination. CIT-albumin interaction is 32 
known; however, the complex formation of DHC with albumin has not been reported 33 
previously. In this study, we aimed to investigate the interaction of DHC with albumin, 34 
employing fluorescence spectroscopy, circular dichroism, and molecular modeling studies. 35 
Furthermore, species differences and thermodynamics of the interaction, as well as the effects 36 
of albumin on the acute in vitro toxicity of DHC and CIT were also tested. Our main 37 
observations/conclusions are as follows: (1) Fluorescence signal of DHC is strongly enhanced 38 
by albumin. (2) Formation of DHC-albumin complexes are supported by both fluorescence 39 
spectroscopic and circular dichroism studies. (3) DHC forms similarly stable complexes with 40 
human albumin (K ~ 105 L/mol) as CIT. (4) DHC-albumin interaction did not show 41 
significant species differences (tested with human, bovine, porcine, and rat albumins). (5) 42 
Based on modeling studies and investigations with site markers, DHC occupies the Heme 43 
binding site (subdomain IB) on human albumin. (6) The presence of albumin significantly 44 
decreased the acute in vitro cytotoxic effects of both DHC and CIT on MDCK cell line. 45 
 46 
Keywords: Dihydrocitrinone; Citrinin; Serum albumin; Fluorescence spectroscopy; Albumin-47 
ligand interaction  48 
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Introduction 49 
Citrinin (CIT; Fig. 1) is a nephrotoxic mycotoxin produced by filamentous fungi, including 50 
Penicillium, Monascus, and Aspergillus genera (de Oliveira Filho et al., 2017). CIT appears as 51 
a contaminant in cereals, cereal-based products, fruits, nuts, and spices (Bennett and Klich, 52 
2003; de Oliveira Filho et al., 2017). Several CIT-producing fungi are used in food industry 53 
during the production of cheese or some Asian foods. Monascus purpureus is applied even 54 
nowadays as a natural food colorant, despite the fact that it commonly produces CIT (da 55 
Rocha et al., 2014). The frequent occurrence of CIT in food was likely responsible for the 56 
“yellow rice toxins” syndrome/disease in Japan (1971) (Ciegler and Bennett, 1980). 57 
Antibacterial activity of CIT has also been reported because some Gram-positive bacteria are 58 
sensitive to CIT; however, it is not used in the pharmacotherapy due to its nephrotoxic effect 59 
in humans and animals (de Oliveira Filho, et al., 2017). Based on our current knowledge, the 60 
chronic CIT exposure may play a role in the development of endemic nephropathy in pigs and 61 
in human  (Flajs and Peraica, 2009; Peraica et al., 2008). After oral exposure, CIT is 62 
extensively biotransformed in humans, during which its major urinary metabolite, 63 
dihydrocitrinone (DHC; Fig. 1) is formed (Ali et al., 2015; Huybrechts et al., 2014; Gerding et 64 
al. 2015; Degen et al., 2018). Based on previous reports, DHC appears in a wide 65 
concentration range in human blood and urine samples (0.00-1.44 ng/mL and 0.01-2.75 66 
ng/mL, respectively) (Ali et al., 2015; Huybrechts et al., 2014; Gerding et al., 2015; Ali et al., 67 
2018). The conversion of CIT to DHC is known as a detoxification reaction, due to the 68 
production of the more polar and less toxic metabolite. In vitro cellular toxicity and 69 
genotoxicity of DHC is significantly lower compared to the parent compound (Dunn et al., 70 
1983; Föllmann et al., 2014). Under acidic conditions, CIT expresses strong fluorescence (λex 71 
= 330 nm; λem = 505 nm); however, fluorescence signal of CIT strongly decreases with the 72 
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elevation of the pH and disappears approximately at pH 5, due to the deprotonation of the 73 
molecule (Poór et al., 2016). 74 
Human serum albumin (HSA) is the most abundant protein in the human circulation. HSA 75 
maintains the oncotic pressure of the blood and displays buffering, antioxidant, and pseudo-76 
enzymatic activities (Fanali et al., 2012). HSA forms stable complexes with several 77 
endogenous and exogenous compounds (Fanali et al., 2012; Yamasaki et al., 2013). HSA 78 
consists of three domains (I, II, and III), each domain is built up from two subdomains (A and 79 
B). The most important binding sites on HSA are Sudlow’s site I (subdomain IIA) and 80 
Sudlow's site II (subdomain IIIA); however, recent studies draw the attention to the 81 
importance of Heme binding site (subdomain IB) (Fanali et al., 2012; Zsila, 2013). The 82 
interaction of CIT with HSA and with albumins from other species has been described 83 
(Damodaran, 1977; Damodaran and Shanmugasundaram, 1978; Poór et al., 2015); on the 84 
other hand, the DHC-albumin complex formation has not been reported. CIT binds to HSA 85 
with similar affinity to the oral anticoagulant warfarin (K = 2 x 105 L/mol), and its binding 86 
site is located in Sudlow’s site I (Poór et al., 2015). 87 
In this study, the complex formation of DHC with albumin was investigated employing 88 
fluorescence spectroscopy, circular dichroism, and molecular modeling. Stability of formed 89 
DHC-albumin complexes were evaluated based on the fluorescence quenching effect of DHC 90 
on albumins. Furthermore, binding constants were also determined, based on the fluorescence 91 
enhancement of DHC by albumins. To test the potential species differences, interaction of 92 
DHC with human, bovine (BSA), porcine (PSA), and rat (RSA) serum albumins was 93 
investigated. To get a deeper insight into the DHC-HSA complex formation, circular 94 
dichroism and thermodynamic studies were performed. Binding site of DHC on HSA was 95 
evaluated based on modeling studies and experiments with site markers. Finally, to 96 
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investigate the influence of albumin on the cellular uptake of the mycotoxin, acute toxicity of 97 
DHC and CIT was tested in MDCK kidney cell line, in the absence and presence of albumin.  98 
 99 
Materials and Methods 100 
Reagents 101 
All reagents and solvents were of analytical or spectroscopic grade. The chemical synthesis of 102 
(±)-dihydrocitrinone (DHC, MW = 266.25 g/mol) was carried out according to the synthetic 103 
procedure for (±)-[13C3]-dihydrocitrinone described by Bergmann et al. (Bergmann et al., 104 
2018), while (+)-DHC was purchased from AnalytiCon Discovery (Potsdam, Germany). As 105 
the natural metabolite (+)-DHC has only limited availability, most studies were performed 106 
with synthetic (±)-DHC and only the circular dichroism experiments with (+)-DHC. Citrinin 107 
(CIT, MW = 250.25 g/mol), human serum albumin (HSA, MW = 66.4 kDa), bovine serum 108 
albumin (BSA, MW = 66.4 kDa), porcine serum albumin (PSA, MW = 67.5 kDa), rat serum 109 
albumin (RSA, MW = 64.6 kDa), ochratoxin A (MW = 403.8 g/mol), warfarin (WAR, MW = 110 
308.33), phenylbutazone (MW = 308.37 g/mol), furosemide (MW = 330.74 g/mol), ibuprofen 111 
(MW = 206.28 g/mol), methyl orange (MW = 327.34 g/mol), bilirubin (MW = 584.66 g/mol), 112 
zearalenone (MW = 318.36 g/mol), L-thyroxine (MW = 776.87 g/mol), and Dulbecco’s 113 
Modified Eagle Medium (DMEM) were purchased from Sigma-Aldrich. Fetal bovine serum 114 
(FBS, from Pan-Biotech) and Bioluminescent ATP Assay Kit CLSII (from Roche) were used 115 
as received. Stock solution of DHC (2500 µmol/L, 0.666 g/L), CIT (2500 µmol/L, 0.626 g/L), 116 
ochratoxin A (5000 µmol/L, 2.019 g/L), zearalenone (5000 µmol/L, 1.592 g/L), ibuprofen 117 
(2500 µmol/L), furosemide (2500 µmol/L), phenylbutazone (2500 µmol/L), warfarin (2500 118 
µmol/L), and L-thyroxine (2500 µmol/L)were prepared in 96 v/v% ethanol (Renal, 119 
spectroscopic grade); while methyl orange (2000 µmol/L) and bilirubin (500 µmol/L) were 120 
dissolved in dimethyl sulfoxide (Fluka, spectroscopic grade). Stock solutions were stored at -121 
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20 °C protected from light. To mimic extracellular physiological conditions, measurements 122 
were carried out in phosphate-buffered saline (PBS: 8.00 g/L NaCl, 0.20 g/L KCl, 1.81 g/L 123 
Na2HPO4 × 2H2O, 0.24 g/L KH2PO4; pH 7.4). 124 
 125 
Spectroscopic measurements 126 
Steady-state fluorescent spectroscopic and fluorescence anisotropy measurements were 127 
carried out employing a Hitachi F-4500 fluorescence spectrophotometer (Tokyo, Japan). 128 
Analyses were performed at 25 °C (except thermodynamic studies) in the presence of air. In 129 
order to exclude the inner filter effect, UV-Vis spectra of DHC, CIT, warfarin, 130 
phenylbutazone, furosemide, ibuprofen, methyl orange, bilirubin, zearalenone, and L-131 
thyroxine were also recorded, applying a Specord Plus 210 (Analytic Jena AG, Jena, 132 
Germany) spectrophotometer. Fluorescence emission intensities were corrected with the 133 
following equation (Hu and Liu, 2015): 134 
𝐼𝑐𝑜𝑟  =  𝐼𝑜𝑏𝑠 ∗ 𝑒
(𝐴𝑒𝑥+𝐴𝑒𝑚)/2       (1) 135 
where Icor and Iobs denote the corrected and observed fluorescence emission intensities, 136 
respectively; while Aex and Aem are the absorbance values of compounds (DHC, CIT 137 
ibuprofen, warfarin, phenylbutazone, furosemide, methyl orange, bilirubin, zearalenone, L-138 
thyroxine) at the excitation and emission wavelengths used, respectively. 139 
During fluorescence quenching studies, increasing concentrations of DHC (0.0, 0.5, 1.0, 2.0, 140 
3.0, and 4.0 μmol/L; 0.00-1.07 mg/L range) were added to standard amount of albumin (2 141 
μmol/L) in PBS (pH 7.4). Quenching experiments were evaluated based on the Stern-Volmer 142 
equation (Hu and Liu, 2015): 143 
𝐼0
𝐼
= 1 + 𝐾𝑆𝑉 ∗ [𝑄]         (2) 144 
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where I0 and I are fluorescence intensities of albumin without and with DHC, respectively (λex 145 
= 295 nm, λem = 340 nm), KSV is the Stern-Volmer quenching constant (unit: L/mol), while 146 
[Q] is the concentration of the quencher (unit: mol/L). 147 
Binding constants (K) of DHC-albumin complexes were determined by non-linear fitting, 148 
using the Hyperquad2006 program package (Protonic Software), during which the following 149 
equations were implemented in the Hyperquad code (SA: serum albumin) (Faisal et al., 2018): 150 
𝑝𝑆𝐴 + 𝑞𝐷𝐻𝐶 ↔ 𝑆𝐴𝑝𝐷𝐻𝐶𝑞        (3) 151 
𝛽𝑝𝑞 =
[𝑆𝐴𝑝𝐷𝐻𝐶𝑞]
[𝑆𝐴]𝑝[𝐷𝐻𝐶]𝑞
         (4) 152 
where p and q indicate the stoichiometry of the equilibrium in the solution. In Hyperquad2006 153 
computer fitting program all equilibrium constants were defined as overall binding constants 154 
(see below).  155 
𝑆𝐴 + 𝐷𝐻𝐶 ↔ 𝑆𝐴 𝐷𝐻𝐶      𝛽1 =
[𝑆𝐴 𝐷𝐻𝐶]
[𝑆𝐴][𝐷𝐻𝐶]
       (5) 156 
𝑆𝐴 + 𝑞𝐷𝐻𝐶 ↔ 𝑆𝐴 𝐷𝐻𝐶𝑞      𝛽𝑞 =
[𝑆𝐴 𝐷𝐻𝐶𝑞]
[𝑆𝐴][𝐷𝐻𝐶]𝑞
     (6) 157 
The relationship between the overall binding constants and the stepwise binding constants were 158 
calculated by the Hyperquad based on the followings. 159 
𝛽1 = 𝐾1;   𝛽𝑞 = 𝐾1 × 𝐾2 … × 𝐾𝑞       (7) 160 
The stoichiometry and binding constant of DHC-albumin complexes were determined using the 161 
model associated with the lowest standard deviation.  162 
Fluorescence spectra of DHC and DHC-albumin complexes were recorded applying 325 and 163 
405 nm as excitation and emission wavelengths, respectively. Increasing albumin 164 
concentrations (0, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.5, and 15.0 µmol/L) were 165 
added to standard amount of DHC (2 µmol/L, 0.533 mg/L) in PBS (pH 7.4). Binding 166 
constants were determined by the Hyperquad2006 software (see Eqs. 3-7). 167 
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To investigate the displacement of DHC from HSA by site markers, increasing concentrations 168 
of ibuprofen, phenylbutazone, furosemide, methyl orange, bilirubin, zearalenone, and L-169 
thyroxine (0, 1, 2, 4, and 6 µmol/L each) were added to standard amount of DHC and HSA (2 170 
and 4 µmol/L, respectively). Fluorescence emission spectra were recorded in PBS (pH 7.4) 171 
using the wavelength maximum of DHC-albumin complexes (λex = 325 nm, λem = 405 nm). 172 
Since the complex formation of DHC with albumin results in significant enhancement of the 173 
fluorescence of the mycotoxin metabolite, displacement of DHC from HSA leads to the 174 
significant decrease of its fluorescence signal.  175 
Thereafter, the influence of DHC (vs. CIT and warfarin) on the fluorescence anisotropy of 176 
ochratoxin A-HSA complex was examined using the previously described method (Poór et 177 
al., 2015). Increasing concentrations of DHC, CIT, and warfarin (0-30 µmol/L each) were 178 
added to standard amounts of ochratoxin A and HSA (1 µmol/L and 1.5 µmol/L, respectively) 179 
in PBS (pH 7.4). Then fluorescence anisotropy values of these samples were determined using 180 
394 and 447 nm as excitation and emission wavelengths, respectively (wavelength maxima of 181 
albumin-bound ochratoxin A). Fluorescence anisotropy (r) data were calculated employing 182 
the following equation (Lakowicz, 2006): 183 
𝑟 =
(𝐼𝑉𝑉−𝐺×𝐼𝑉𝐻)
(𝐼𝑉𝑉+2×𝐺×𝐼𝑉𝐻)
        (8) 184 
where G is the instrumental factor, IVV and IVH are emission intensities measured in vertical 185 
position of polarizer at pre-sample site, and at vertical and horizontal position of post-sample 186 
polarizer, respectively. 187 
 188 
Circular dichroism  189 
The circular dichroism spectra of (+)-DHC were measured at room temperature using a 1 cm 190 
cell with a Jasco J-600 CD spectrometer (Jasco, Groß-Umstadt, Germany). The spectra were 191 
recorded between 200-270 nm with 1 nm step size, 1 nm bandwidth, 100 nm/min speed and 192 
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an average time of 0.5 s. Five measurements from each sample were performed and averaged 193 
without using the smoothing function. Two different DHC concentrations (0.48 µmol/L = 194 
0.128 mg/L and 0.96 µmol/L = 0.256 mg/L) were incubated in duplicates with 0.48 µmol/L 195 
HSA in 30 mmol/L phosphate buffer (4.4 g/L Na2HPO4, 0.6 g/L KH2PO4, pH was adjusted to 196 
7.4 with 0.1 mol/L H3PO4) for 5 h at room temperature while shaking. The same HSA 197 
solution at a concentration of 0.48 µmol/L (determined by Bradford assay) was used for all 198 
experiments. Ellipticity (θMRE) was used for converting the observed ellipticity (θobs) to the 199 
mean residue based on the following equation: 200 
θMRE = 
θobs
10 x Cp x n x l
        (9) 201 
where Cp is the protein concentration (4.8 x 10
-7 mol/L), n is the number of amino acids of 202 
HSA (584) and l is the length of the cuvette (1 cm). For the calculation of the α-helix 203 
percentage, the following equation was employed, and software K2D3 was utilized (Wang et 204 
al., 2013; Ajmal et al., 2017; Louis-Jeune et al., 2012). 205 
α-helix (%) = 
-θMRE 208nm - 4000
33000 - 4000
 x 100      (10) 206 
For the K2D3 software the θMRE from 200-240 nm and the protein size of 584 amino acids 207 
were applied. 208 
 209 
Thermodynamic studies 210 
To get a deeper insight into the DHC-HSA interaction, thermodynamic parameters were 211 
determined, during which binding constants of complexes were calculated at six different 212 
temperatures (298, 301, 304, 307, 310, and 313 K). Binding constants (K) were quantified 213 
based on fluorescence spectroscopic measurements employing the Hyperquad2006 software 214 
(see Eqs. 3-7), using 325 and 405 nm excitation and emission wavelengths, respectively. 215 
Thermodynamic parameters associated to the complex formations between DHC and HSA 216 
were determined using the van’t Hoff equation:  217 
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𝑙𝑜𝑔𝐾 = −
∆𝐺
𝑅𝑇
= −
∆𝐻
2.303×𝑅×𝑇
+
∆𝑆
2.303×𝑅
     (11) 218 
where ΔG, ΔH, and ΔS reflect the Gibbs free energy, enthalpy, and entropy changes of the 219 
binding reaction, respectively; while R refers to the gas constant and T is the temperature. 220 
 221 
Modeling studies 222 
The ligand structure was built in Maestro (Schrödinger, 2017). The raw structure was energy 223 
minimized, using the semi-empirical quantum chemistry program package, MOPAC (Stewart, 224 
1990) and the PM6 parameterization (Stewart, 2007). The gradient norm was set to 0.001. 225 
The energy minimized structure was subjected to force calculations. The force constant 226 
matrices were positive definite. The minimized ligand structures were then used in our 227 
docking calculations. 228 
An apo crystallographic structure (PDB code: 1ao6) of HSA was used as target molecule in 229 
our calculations. Acetyl and amide capping groups were attached to the N- and C-termini, 230 
respectively, using the Schrödinger Maestro program package v. 9.6 (Schrödinger, 2017). As 231 
1ao6 contains a homodimer structure, only chain A was used for calculations. Co-crystallized 232 
ions and water molecules were removed before minimizing the protein structure. The target 233 
molecule was minimized using a two-step protocol with the GROMACS software package 234 
(Abraham et al., 2015), including a steepest descent and a conjugate gradient step, and using 235 
AMBER99-ildn force field (Lindorff-Larsen et al., 2010). Exit tolerance levels were set to 236 
1000 and 10 kJ mol−1 nm−1 while maximum step sizes were set to 0.5 and 0.05 nm, 237 
respectively. The minimized target was then used in our docking calculations. 238 
Using the optimized ligand and target structures, blind docking calculations were performed 239 
with AutoDock 4.2 program package (Morris et al., 2009) as described in our previous 240 
publications (Poór et al., 2015; Hetényi and van der Spoel, 2002, 2006, 2011). Gasteiger-241 
Marsilli partial charges were added to both the ligand and target atoms, using AutoDock 242 
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Tools (Morris et al., 2009) and united atom representation was applied for non-polar moieties. 243 
A grid box of 250 × 250 × 250 points, and 0.375 Å spacing was calculated and centered on 244 
target center of mass by AutoGrid 4. Lamarckian genetic algorithm was used for global 245 
search. Flexibility was allowed on the ligand at all active torsions, number of docking runs 246 
was set to 100, numbers of energy evaluations and generations were 20 million (Hetényi and 247 
van der Spoel, 2006). Ligand conformations that resulted from the docking runs were ordered 248 
by the corresponding calculated interaction energy values and subsequently clustered using a 249 
tolerance of 1.75 Å root mean square deviation (RMSD) between cluster members (Hetényi 250 
and van der Spoel, 2002). 251 
 252 
Cell cultures and ATP-based cell viability assay 253 
MDCK (Madin-Darby canine kidney epithelial cells, ATCC: CCL-34) adhesion cell line was 254 
cultured in DMEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin 255 
(100 µg/mL), in a humidified atmosphere (5% CO2) at 37 °C. Trypsinized cells were plated in 256 
96-well plastic plates (approximately 104 cells/well). Before the treatment, the culture 257 
medium was replaced with fresh one (without FBS/HSA, with FBS, or with HSA), then cells 258 
were incubated with 50 µmol/L (DHC: 13.313 mg/L; CIT: 12.513 mg/L) or 100 µmol/L 259 
(DHC: 26.625 mg/L; CIT: 25.025 mg/L) mycotoxin concentrations in the absence and in the 260 
presence of 10% FBS or 40 g/L HSA. After 24-h incubation, ATP levels were quantified 261 
applying the previously described method without any modifications (Sali et al., 2016). 262 
 263 
Statistics 264 
Means and standard error (± SEM) values expressed in figures. Statistical evaluation of 265 
experiments with site markers and in vitro cell experiments were carried out using one-way 266 
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ANOVA test (IBM SPSS Statistics, Version 21), during which the level of significance was 267 
set at p < 0.05 and p < 0.01. 268 
 269 
Results and Discussion 270 
Fluorescence spectroscopic investigation of DHC in the absence and presence of HSA 271 
First, the fluorescence excitation and emission spectra of DHC were recorded in PBS (pH 272 
7.4). Despite the parent compound (CIT) does not express fluorescence at physiological pH 273 
(Poór et al., 2016), conversion of CIT to DHC leads to significant spectral changes. As Fig. 274 
S1 demonstrates, DHC showed fluorescence property in PBS, exerting its excitation and 275 
emission wavelength maxima at 325 and 420 nm, respectively. 276 
Because interaction of fluorophores with albumin can lead to changes in their fluorescence 277 
(Sueck et al., 2018), the influence of HSA on the fluorescence emission spectrum of DHC 278 
was tested. Increasing amounts of HSA (final concentrations: 0-15 μmol/L) were added to 279 
DHC (2 μmol/L) in PBS, then emission spectra were recorded (λex = 325 nm). In a dose 280 
dependent fashion, HSA caused a significant fluorescence enhancement of DHC, during 281 
which the blue shift of the emission wavelength maximum of DHC (420 → 405 nm) was 282 
noticed (Fig. 2a). Under the applied conditions, HSA also shows some fluorescence emission; 283 
however, the increase in fluorescence resulted from the presence of HSA is relatively low 284 
(Fig. 2b). Considering the highest molecular orbital of DHC, the aromatic moiety takes part in 285 
the fluorescence process through two ways: (a) the interaction of the aromatic ring in DHC 286 
with the surface of albumin modifies the fluorescence efficiency of the aromatic moiety; (b) 287 
the partial removal of water molecules from the solvation shell of DHC, prior its interaction 288 
with the albumin, enhances the fluorescence of DHC due to the reduced number of the 289 
quencher water molecules in the solvation shell. These observations strongly suggest the 290 
formation of DHC-HSA complexes. Since the increased fluorescence at 405 nm is partly 291 
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originating from the fluorescence signal of HSA, emission intensities were corrected during 292 
the calculation of binding constants (see later in Binding constants of DHC-albumin 293 
complexes section). 294 
 295 
Fluorescence quenching of HSA by DHC 296 
Fluorescence emission spectrum of HSA (2 µmol/L) was recorded in PBS (pH 7.4), in the 297 
absence and presence of increasing concentrations of DHC (0-4 µmol/L; λex = 295 nm, λem = 298 
340 nm). Using 295 nm as excitation wavelength, HSA shows emission maximum at 340 nm, 299 
while a second peak at higher wavelength (approximately at 405 nm) also appears in the 300 
presence of DHC, due to the fluorescence emission of DHC and DHC-HSA complex (Fig. 301 
3a). In a concentration dependent fashion, DHC induced the decrease of the fluorescence 302 
signal at 340 nm as a result of the fluorescence quenching effect of DHC on HSA. To exclude 303 
the inner-filter effect, fluorescence signal of HSA was corrected based on Eq. 1. The good 304 
linearity of the Stern-Volmer plot (R2 = 0.993) recommends 1:1 stoichiometry of complex 305 
formation. The decrease in the slope of the Stern-Volmer plot at higher temperature values 306 
suggests the static quenching process of HSA by DHC (see below in the Thermodynamics of 307 
DHC-HSA complex formation section). 308 
 309 
Binding constants of DHC-albumin complexes  310 
In order to evaluate the stability of DHC-albumin complexes and the potential species 311 
differences of DHC-albumin interactions, experiments described in the previous two sections 312 
were performed with bovine (BSA), porcine (PSA), and rat (RSA) serum albumins. Similarly 313 
to HSA, other albumins also induced the significant fluorescence enhancement of DHC (Fig. 314 
S2). The strongest enhancers were HSA and RSA causing approximately 75-fold increase in 315 
the fluorescence of DHC, while the less effective enhancers BSA and PSA led to the 60-fold 316 
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and 25-fold elevation of fluorescence, respectively. Fluorescence quenching effect of DHC 317 
was the highest in the presence of RSA, followed by HSA and BSA, while the lowest 318 
decrease of fluorescence was observed with PSA (Fig. 3b). 319 
Quantitation of binding constants were determined using both models: (a) enhancement of the 320 
fluorescence of DHC by albumins (Fig. S2), and (b) quenching the fluorescence of albumins 321 
by DHC (Fig. 3). Decimal logarithmic values of Stern-Volmer quenching constants (KSV; unit: 322 
L/mol) and binding constants (K; unit: L/mol) are demonstrated in Table 1 for each examined 323 
DHC-albumin complexes. The logKSV values determined based on the Stern-Volmer equation 324 
(Eq. 2) were in a good correlation with the logK values calculated using the Hyperquad 325 
program (Eqs. 3-7). The quenching model suggests somewhat lower binding constants 326 
compared to the other approach; however, the tendencies of species differences are similar in 327 
both models. DHC forms the most stable complex with RSA, followed by HSA, BSA, and 328 
PSA. The stability of DHC-RSA complex is approximately 4-5 times higher compared to 329 
DHC-PSA, however, only moderate species differences were observed during the comparison 330 
of the binding constant of DHC-HSA with other DHC-albumin complexes. Albumin-binding 331 
of some mycotoxins shows large species-dependent differences, for example ochratoxin A 332 
and zearalenone/zearalenols (Faisal et al., 2018). From this point of view, DHC behaves very 333 
similarly to the parent compound CIT; the latter binds to HSA with almost the same affinity 334 
(logK = 5.32) and shows similar species differences to DHC (Poór et al., 2015). 335 
 336 
Circular dichroism (CD) of HSA with DHC 337 
CD is a useful analytical tool for the characterization of the secondary structure of proteins as 338 
the absorption of the circularly polarized light between 200 and 240 nm provides information 339 
on the percentage of α-helices and β-sheets of a protein (Wang et al., 2013). Based on the 340 
limited availability of the natural isomer (+)-DHC, it was examined only in CD experiments 341 
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(other studies were performed with (±)-DHC). In order to recognize changes in the secondary 342 
structure of HSA in the presence of (+)-DHC, CD-spectra of the single compounds and their 343 
mixture were recorded in the 200-270 nm range. For the CD experiments, a 0.48 µmol/L 344 
concentration of HSA in 30 mmol/L phosphate buffer (pH 7.4) was used and for the 345 
incubation of HSA with (+)-DHC at equimolar concentration. While (+)-DHC did not show a 346 
CD effect, characteristic CD spectra for HSA and the mixture of HSA and (+)-DHC were 347 
recorded (Fig. 4). 348 
The mean residue ellipticity (θMRE) of the native HSA at the characteristic wavelength minima 349 
of 208 nm and 222 nm indicate that the native protein had predominantly α-helix secondary 350 
structure (Fig. 4). The characteristic minima that are indicative for the α-helices are caused by 351 
amino acids of the protein (Wang et al., 2013). In the presence of DHC, a slight increase of 352 
θMRE was observed at these characteristic wavelengths of 208 nm and 222 nm. These 353 
observations suggest that the complex formation of DHC with HSA leads to a slight change in 354 
the secondary structure of HSA, resulting in a decrease of α-helicity (Fig. 4). The native HSA 355 
had α-helix percentage of 67.4 to 73.3% (Table 2). After incubation with DHC, the α-helicity 356 
of HSA was reduced by 3-9%, suggesting the formation of DHC-HSA complexes. HSA (0.48 357 
µmol/L) was also incubated with double equivalent concentration of DHC (0.98 µmol/L) 358 
under the same conditions, during which no further increase of the θMRE was observed. 359 
 360 
Thermodynamics of DHC-HSA complex formation 361 
The temperature dependence of the binding constants of DHC-HSA complex was investigated 362 
between 298 and 313 K. Similarly to the CIT-HSA complex (Poór et al., 2015), the logK values 363 
of DHC-HSA show higher stability at lower temperatures, reflecting the presence of ground 364 
state complexes. Fig. S3 demonstrates the van’t Hoff plot of DHC-HSA complex, and the 365 
thermodynamic parameters derived from the slope and the intercept of the line fitted to the logK 366 
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values (Eq. 11). H and S associated to the DHC-HSA complex formation were found to be -367 
22.65 kJ mol-1 and +23.29 J K-1 mol-1, respectively.  The calculated negative G value (-29.78 368 
kJ mol-1) suggests the spontaneous binding process between DHC and HSA at room 369 
temperature, and it is within the typical range of non-covalent interactions. These values are 370 
close to the parameters obtained for CIT-HSA interaction (G = -29.96 kJ mol-1, H = -24.15 371 
kJ mol-1, and S = 20.90 J K-1 mol-1) (Poór et al., 2015). Thermodynamic data indicate similar 372 
binding characteristics of DHC-HSA and CIT-HSA complexes, namely electrostatic forces play 373 
a major role in the complex formation. According to the entropy gain of DHC-HSA interaction, 374 
it is reasonable to hypothesize the partial decomposition of the solvation shells of interacting 375 
molecules, leading to a less ordered structure of water molecules (Ross and Subramanian, 376 
1981). 377 
 378 
Modeling studies 379 
Blind docking calculations resulted in 100 ligand conformations, which were further clustered 380 
as described in the Materials and Methods section. After clustering, five ligand conformations 381 
were obtained, which were ordered by the calculated interaction energy between the target 382 
and the ligand molecule. Out of the five clusters, the first four are illustrated in Fig. 5a, and 383 
discussed in the followings. 384 
Each analyzed docking rank bound to known binding pockets (Fanali et al., 2012). The first 385 
rank (Rank 1) bound to the Sudlow’s site I (binding site of the oral anticoagulant warfarin; 386 
Fig. S4a), the second rank (Rank 2) partially occupied the FA9 binding site (near to one of the 387 
binding sites of L-thyroxine; Fig. S4b), the third rank (Rank 3) bound to approximately 10Å 388 
distance from the binding site of mycotoxin zearalenone (Fig. S4c) (Faisal et al., 2018), and 389 
the fourth rank (Rank 4) bound to the Heme binding site (FA1; one of its typical ligands is 390 
bilirubin; Fig. S4d). 391 
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The binding conformation of Rank 4 DHC interacts with both hydrophobic (L115, I142) and 392 
hydrophilic (R114, H146, R145, R186, K190) amino acids in the Heme binding site (Fig. 5b). 393 
The DHC is secured in the Heme site through H-bonds and salt bridges between the 394 
hydrophilic amino acids and the carboxyl and hydroxyl groups of the DHC. The hydrophobic 395 
interactions act between L115 and I142 amino acids and the methyl groups of the DHC. 396 
 397 
Investigation of the binding site of DHC on HSA using site markers 398 
To examine the binding site of DHC on HSA, some typical ligands of Sudlow’s site I 399 
(phenylbutazone and furosemide), Sudlow’s site II (ibuprofen), and Heme binding site 400 
(bilirubin and methyl orange) were applied (Fanali et al., 2012; Zsila, 2013). Furthermore, to 401 
test the potential involvement of Rank 2 (FA9) or Rank 3 as binding sites, the effects of L-402 
thyroxine and zearalenone on DHC-HSA interaction was also tested. In these experiments, 403 
our previous observation that albumin-binding significantly increases the fluorescence signal 404 
of DHC was utilized (Fig. 2). Using this principle, it is reasonable to hypothesize that the 405 
displacement of DHC from albumin leads to the significant decrease in its fluorescence at 405 406 
nm (emission wavelength maximum of HSA-bound DHC). Therefore, fluorescence emission 407 
spectrum of DHC-HSA complex (2 and 4 µmol/L, respectively) was recorded in the presence 408 
of increasing concentrations of site markers (0, 1, 2, 4, and 6 µmol/L) in PBS (λex = 325 nm). 409 
The concentrations of solvents did not exceed 1.2 v/v% which did not influence the 410 
fluorescence of DHC-HSA complex in the absence of site markers. As Fig. 6a demonstrates, 411 
the presence of L-thyroxine, zearalenone, and the markers of Sudlow’s site I and II induced 412 
negligible changes in the fluorescence of DHC-HSA complex. On the other hand, both 413 
markers of the Heme binding site (methyl orange and bilirubin) significantly decreased the 414 
fluorescence at 405 nm, suggesting the displacement of DHC from HSA by these compounds, 415 
and the involvement of the Heme binding site regarding DHC-HSA interaction. The binding 416 
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constant of bilirubin-HSA complex is much higher compared to methyl orange-HSA (Ahlfors, 417 
1981; Zsila, 2013), which is in agreement with our observation that bilirubin can induce 418 
stronger displacement of DHC from HSA compared to methyl orange. 419 
Previous investigations revealed that CIT occupies Sudlow’s site I as its primary binding site 420 
on HSA (Poór et al., 2015). Since the binding constant, the binding mode, and species 421 
differences of DHC-albumin complex are very similar to the CIT-albumin complex, it is 422 
surprising that DHC occupies another binding site than CIT. Thus, to confirm these results, 423 
further experiments were performed with the known markers of site I, namely warfarin and 424 
ochratoxin A (Il’ichev et al., 2002). During this experiment, our previously described model 425 
was employed (Poór et al., 2015). Since ochratoxin A is a small fluorophore, its interaction 426 
with the macromolecule (HSA) results in the significant decrease in its rotational freedom and 427 
consequently the strong increase of fluorescence polarization or anisotropy values of the 428 
mycotoxin. Based on these principles, albumin-binding of ochratoxin A can be precisely 429 
followed by fluorescence polarization or anisotropy techniques (Poór et al., 2015). 430 
Fluorescence anisotropy of ochratoxin A with HSA (1.0 and 1.5 µmol/L, respectively) were 431 
determined in the presence of increasing concentrations of DHC, CIT, or warfarin (each 0, 1, 432 
5, 10, 20, and 30 µmol/L). CIT and warfarin induced similar (but statistically not significant) 433 
decrease in the fluorescence anisotropy of ochratoxin A, while DHC caused only a slight 434 
effect (Fig. 6b). Since the decrease in fluorescence anisotropy is resulted from the increased 435 
rotational freedom of ochratoxin A, this observation suggests the displacement of ochratoxin 436 
A from HSA in the presence of CIT and warfarin. The fact that even relatively large 437 
concentrations of DHC failed to significantly decrease the anisotropy value of ochratoxin A 438 
supports our previous finding that the binding site of DHC is not located in Sudlow’s site I. 439 
 440 
Influence of albumin on the acute cellular toxicity of DHC and CIT 441 
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In order to examine the influence of albumin on the acute cellular toxicity of DHC and CIT, 442 
MDCK kidney cells were treated with these mycotoxins in the absence and presence of 10% 443 
FBS or 40 g/L HSA. Cell culture media usually contains 10% FBS (final concentration of 444 
BSA: approximately 3.5 g/L), while 40 g/L is a typical HSA concentration in the human 445 
blood. Since the acute cytotoxicity of DHC and CIT is relatively low, high mycotoxin 446 
concentrations (50 and 100 μmol/L) were applied to produce remarkable toxic effects. Each 447 
sample (including the control) contained the same ethanol concentrations (4 v/v%, which was 448 
the solvent of CIT and DHC). Mycotoxin-induced loss of cell viability was evaluated based 449 
on ATP levels/well after 24-h incubation. As Fig. 7 demonstrates, the applied mycotoxin 450 
concentrations caused significant decrease of ATP. In agreement with previous studies, the 451 
lower toxicity of DHC was observed compared to CIT (Föllmann et al., 2014). In the presence 452 
of FBS and HSA, the cytotoxicity of both CIT and DHC significantly decreased (Fig. 7), most 453 
likely due to the formation of stable mycotoxin-albumin complexes which can limit the 454 
cellular uptake of these mycotoxins. Stronger effect of HSA (vs. FBS) can be mainly 455 
attributed to the lower BSA concentration in the cell medium (3.5 g/L BSA vs. 40 g/L HSA). 456 
Therefore, our results demonstrate that the interaction of DHC with albumin may significantly 457 
affect the tissue uptake of the mycotoxin. 458 
In conclusion, the interaction of DHC with albumin was investigated by fluorescence 459 
spectroscopy, circular dichroism, and molecular modeling. Binding constant and binding site, 460 
species-dependent alternations, and thermodynamics of the interaction were characterized, as 461 
well as the effects of albumin on the in vitro cytotoxicity of DHC and CIT were also tested. 462 
DHC exerts fluorescence signal at physiological conditions, which is strongly enhanced by 463 
albumin. Besides the increased fluorescence of DHC in the presence of albumins, the 464 
formation of DHC-albumin complexes is also supported by fluorescence quenching and 465 
circular dichroism studies. Stability of DHC-HSA, DHC-BSA, and DHC-PSA complexes 466 
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were similar, while DHC binds to RSA with slightly higher affinity compared to other 467 
albumins tested. Binding constant of DHC-HSA complex is similar to CIT-HSA; however, 468 
DHC occupies Heme binding site (FA1; subdomain IB) on HSA while CIT is a ligand of 469 
Sudlow’s Site I (subdomain IIA). Thermodynamic studies suggest the spontaneous binding 470 
process between DHC and HSA at room temperature, during which electrostatic forces play a 471 
major role. Furthermore, the partial decomposition of the solvation shells can be assumed. 472 
Albumin decreased significantly the toxic effects of both DHC and CIT on MDCK cells, 473 
which also confirms the formation of stable mycotoxin-albumin complexes.  474 
 475 
Source of Funding 476 
This project was supported by the Hungarian National Research, Development and Innovation 477 
Office (FK125166) (M.P.) and the Deutsche Forschungsgemeinschaft (GRK1143, IRTG 478 
Münster-Nagoya) (H.H.). The work of M.B. and C.H. was supported by the Hungarian 479 
National Research, Development and Innovation Office (K123836). 480 
 481 
Acknowledgements 482 
This project was supported by the János Bolyai Research Scholarship of the Hungarian 483 
Academy of Sciences (M.P.). M.P. is thankful for support of the University of Pécs for grant 484 
in the frame of Pharmaceutical Talent Centre program. This work was supported by the 485 
GINOP-2.3.2-15-2016-00049 grant. This project was supported by the ÚNKP-18-2 New 486 
National Excellence Program of the Ministry of Human Capacities (V.V.). We acknowledge a 487 
grant of computer time from CSCS Swiss National Supercomputing Centre, and the 488 
Governmental Information Technology Development Agency, Hungary. We acknowledge 489 
that the results of this research have been achieved using the DECI resource Archer based in 490 
the UK at the National Supercomputing Service with support from the PRACE aisbl. The 491 
21 
 
University of Pécs is acknowledged for a support by the 17886-4/23018/FEKUTSTRAT 492 
excellence grant. 493 
 494 
Conflict of interest: The authors declare no conflict of interest. We have full control of all 495 
primary data and we agree to allow the journal to review our data if requested. 496 
 497 
References 498 
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E (2015) GROMACS: 499 
high performance molecular simulations through multi-level parallelism from laptops to 500 
supercomputers. SoftwareX 1:19-25. 501 
https://doi.org/10.1016/j.softx.2015.06.001 502 
 503 
Ahlfors CE (1981) Competitive interaction of biliverdin and bilirubin only at the primary 504 
bilirubin binding site on human albumin. Anal Biochem 110:295-307. 505 
https://doi.org/10.1016/0003-2697(81)90195-0 506 
 507 
Ajmal MR, Nusrat S, Alam P, Zaidi N, Khan MV, Zaman M, Shahein YE, Mahmoud MH, 508 
Badr G, Khan RH (2017) Interaction of anticancer drug clofarabine with human serum 509 
albumin and human α-1 acid glycoprotein. Spectroscopic and molecular docking approach. J 510 
Pharm Biomed Anal, 135:106-115. 511 
https://doi.org/10.1016/j.jpba.2016.12.001 512 
 513 
Ali N, Blaszkewicz M, Degen GH (2015) Occurrence of the mycotoxin citrinin and its 514 
metabolite dihydrocitrinone in urines of German adults. Arch Toxicol 89:573-578. 515 
https://doi.org/10.1007/s00204-014-1363-y 516 
22 
 
 517 
Ali N, Hossain K, Degen GH (2018) Blood plasma biomarkers of citrinin and ochratoxin A 518 
exposure in young adults in Bangladesh. Mycotoxin Res 34:59–67. 519 
https://doi.org/10.1007/s12550-017-0299-5 520 
 521 
Bennett JW, Klich M (2003) Mycotoxins. Clin Microbiol Rev 16:497-516. 522 
https://doi.org/10.1128/CMR.16.3.497–516.2003 523 
 524 
Bergmann D, Hübner F, Wibbeling B, Daniliuc C, Cramer B, Humpf H-U (2018) Large-scale 525 
total synthesis of 13C3-labeled citrinin and its metabolite dihydrocitrinone. Mycotoxin Res 526 
34:141-150. 527 
https://doi.org/10.1007/s12550-018-0308-3 528 
 529 
Ciegler A, Bennett JW (1980) Mycotoxins and Mycotoxicoses. BioScience 30:512-515. 530 
https://doi.org/10.2307/1307970 531 
 532 
da Rocha MEB, Freire FCO, Maia FEF, Guedes MIF, Rondina D (2014) Mycotoxins and 533 
their effects on human and animal health. Food Control 36:59-165. 534 
https://doi.org/10.1016/j.foodcont.2013.08.021 535 
 536 
Damodaran C (1977) In vitro binding of citrinin to serum protein. Experientia 33:598-599. 537 
https://doi.org/10.1007/BF01946519 538 
 539 
Damodaran C, Shanmugasundaram E (1978) Distribution of radioactive citrinin in tissues and 540 
serum protein(s). J Radioanal Chem 46:373-377. 541 
23 
 
https://doi.org/10.1007/BF02519903 542 
 543 
Degena GH, Ali N, Gundert-Remy U (2018) Preliminary data on citrinin kinetics in humans 544 
and their use to estimate citrinin exposure based on biomarkers. Toxicol. Lett. 282:43-48. 545 
http://dx.doi.org/10.1016/j.toxlet.2017.10.006 546 
 547 
de Oliveira Filho JWG, Islam MT, Ali ES, Uddin SJ, Santos JVO, de Alencar MVOB, Júnior 548 
ALG, Paz MFCJ, de Brito MDRM, e Sousa JMC, Shaw S, de Medeiros MDGF, Dantas 549 
SMMM, Rolim HML, Ferreira PMP, Kamal MA, Pieczynska MD, Das N, Gupta VK, Mocan 550 
A, Dos Santos Andrade TJA, Singh BN, Mishra SK, Atanasov AG, Melo-Cavalcante AAC 551 
(2017) A comprehensive review on biological properties of citrinin. Food Chem Toxicol 552 
110:130-141. 553 
https://doi.org/10.1016/j.fct.2017.10.002 554 
 555 
Dunn BB, Stack ME, Park DL, Joshi A, Friedman L, King RL (1983) Isolation and 556 
identification of dihydrocitrinone, a urinary metabolite of citrinin in rats. J Toxicol Environ 557 
Health 12:283-289. 558 
https://doi.org/10.1080/15287398309530426 559 
 560 
Faisal Z, Lemli B, Szerencsés D, Kunsági-Máté S, Bálint M, Hetényi C, Kuzma M, Mayer M, 561 
Poór M (2018) Interactions of zearalenone and its reduced metabolites α-zearalenol and β-562 
zearalenol with serum albumins: species differences, binding sites, and thermodynamics. 563 
Mycotoxin Res. 34:269-278. 564 
https://doi.org/10.1007/s12550-018-0321-6 565 
 566 
24 
 
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P (2012) Human serum 567 
albumin: From bench to bedside. Mol Asp Med 33:209-290. 568 
https://doi.org/10.1016/j.mam.2011.12.002 569 
 570 
Flajs D, Peraica M (2009) Toxicological Properties of Citrinin. Arh Hig Rada Toksikol 571 
60:457-464. 572 
https://doi.org/10.2478/10004-1254-60-2009-1992 573 
 574 
Föllmann W, Behm C, Degen GH (2014) Toxicity of the mycotoxin citrinin and its metabolite 575 
dihydrocitrinone and of mixtures of citrinin and ochratoxin A in vitro. Arch Toxicol 88:1097-576 
1107. 577 
https://doi.org/10.1007/s00204-014-1216-8 578 
 579 
Gerding J, Ali N, Schwartzbord J, Cramer B, Brown DL, Degen GH, Humpf H-U (2015) A 580 
comparative study of the human urinary mycotoxin excretion patterns in Bangladesh, 581 
Germany and Haiti using a rapid and sensitive LC-MS/MS approach. Mycotoxin Res 31:127-582 
136. 583 
https://doi.org/10.1007/s12550-015-0223-9. 584 
 585 
Hetényi C, van der Spoel D (2002) Efficient docking of peptides to proteins without prior 586 
knowledge of the binding site. Protein Sci 11:1729-1737. 587 
https://doi.org/10.1110/ps.0202302 588 
 589 
Hetényi C, van der Spoel D (2006) Blind docking of drug-sized compounds to proteins with 590 
up to a thousand residues. FEBS Lett 580:1447-1450. 591 
25 
 
https://doi.org/10.1016/j.febslet.2006.01.074 592 
 593 
Hetényi C, van der Spoel D (2011) Toward prediction of functional protein pockets using 594 
blind docking and pocket search algorithms. Protein Sci 20:880-893. 595 
https://doi.org/10.1002/pro.618 596 
 597 
Hu T, Liu Y (2015) Probing the interaction of cefodizime with human serum albumin using 598 
multi-spectroscopic and molecular docking techniques. J Pharm Biomed Anal 107:325-332. 599 
https://doi.org/10.1016/j.jpba.2015.01.010 600 
 601 
Huybrechts B, Martins JC, Debongnie Ph, Uhlig S, Callebaut A (2015) Fast and sensitive 602 
LC–MS/MS method measuring human mycotoxin exposure using biomarkers in urine. Arch 603 
Toxicol 89:1993-2005. 604 
https://doi.org/10.1007/s00204-014-1358-8 605 
 606 
Il’ichev YV, Perry JL, Simon JD (2002) Interaction of Ochratoxin A with Human Serum 607 
Albumin. A Common Binding Site of Ochratoxin A and Warfarin in Subdomain IIA. J Phys 608 
Chem B 106:460-465. 609 
https://doi.org/10.1021/jp012315m 610 
 611 
Lakowicz JR (2006) Fluorescence Anisotropy In: Principles of Fluorescence Spectroscopy 612 
3rd edn. Baltimore, Maryland, pp 353-382. 613 
 614 
26 
 
Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE (2010) 615 
Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 616 
78:1950-1958. 617 
https://doi.org/10.1002/prot.22711 618 
 619 
Louis-Jeune C, Andrade-Navarro MA, Perez-Iratxeta C (2012) Prediction of protein 620 
secondary structure from circular dichroism using theoretically derived spectra. Proteins 621 
80:374-381. 622 
https://doi.org/10.1002/prot.23188 623 
 624 
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) 625 
AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J 626 
Comput Chem 30:2785-2791. 627 
https://doi.org/10.1002/jcc.21256 628 
 629 
Peraica M, Domijan AM, Miletic´-Medved M, Fuchs R (2008) The involvement of 630 
mycotoxins in the development of endemic nephropathy. Wien Klin Wochen 120: 402-407. 631 
https://doi.org/10.1007/s00508-008-0981-x 632 
 633 
Poór M, Lemli B, Bálint M, Hetényi C, Sali N, Kőszegi T, Kunsági-Máté S (2015) Interaction 634 
of citrinin with human serum albumin. Toxins 7:5155-5166. 635 
https://doi.org/10.3390/toxins7124871 636 
 637 
27 
 
Poór M, Matisz G, Kunsági-Máté S, Derdák D, Szente L, Lemli B (2016) Fluorescence 638 
spectroscopic investigation of the interaction of citrinin with native and chemically modified 639 
cyclodextrins. J Lumin 172:23-28. 640 
https://doi.org/10.1016/j.jlumin.2015.11.011 641 
 642 
Ross PD, Subramanian S (1981) Thermodynamics of protein association reactions: forces 643 
contributing to stability. Biochemistry 20:3096-3102. 644 
https://doi.org/10.1021/bi00514a017 645 
 646 
Sali N, Nagy S, Poór M, Kőszegi T (2016) Multiparametric luminescent viability assay in 647 
toxicology models: a critical evaluation. J Pharmacol Toxicol Methods 79:45-54. 648 
https://doi.org/10.1016/j.vascn.2016.01.004 649 
 650 
Schrödinger LLC. (2017)  New York, NY  651 
 652 
Stewart JJ. MOPAC 2007 (2007) Version 7, 290 W. Stewart Computational Chemistry, 653 
Colorado Springs, CO 654 
 655 
Sueck F, Poór M, Faisal Z, Gertzen CGW, Cramer B, Lemli B, Kunsági-Máté S, Gohlke H, 656 
Humpf H-U (2018) Interaction of ochratoxin A and its thermal degradation product 2'R-657 
ochratoxin A with human serum albumin. Toxins 10: E256. 658 
https://doi.org/10.3390/toxins10070256 659 
 660 
Wang Q, Yan J, He J, Bai K, Li H (2013) Characterization of the interaction between 3-661 
xotabersonine and two serum albumins by using spectroscopic techniques. J Lumin 138:1-7. 662 
28 
 
https://doi.org/10.1016/j.jlumin.2013.01.035 663 
 664 
Yamasaki K, Chuang VT, Maruyama T, Otagiri M (2013) Albumin-drug interaction and its 665 
clinical implication. Biochim Biophys Acta 1830:5435-5443. 666 
https://doi.org/10.1016/j.bbagen.2013.05.005 667 
 668 
Zsila F (2013) Subdomain IB Is the Third Major Drug Binding Region of Human Serum 669 
Albumin: Toward the Three-Sites Model. Mol Pharmaceutics 10:1668-1682. 670 
https://doi.org/10.1021/mp400027q  671 
29 
 
List of figures: 672 
 673 
Fig. 1 Chemical structures of citrinin and dihydrocitrinone 674 
 675 
Fig. 2 a Fluorescence emission spectrum of DHC (2 μmol/L) in the presence of increasing 676 
HSA concentrations (0-15 µmol/L) in PBS. b Fluorescence emission intensities of HSA 677 
without DHC (IHSA), DHC with HSA (IDHC+HSA), and the difference of DHC+HSA and HSA 678 
(IDHC+HSA - IHSA) (b; λex = 325 nm, λem = 405 nm) (representative spectra and data) 679 
 680 
Fig. 3 a Fluorescence emission spectrum of HSA (2 μmol/L) in the presence of increasing 681 
DHC concentrations (0-4 µmol/L) in PBS (pH 7.4; λex = 295 nm; representative spectra). b 682 
Stern-Volmer plots of DHC-albumin (2 μmol/L albumin and 0-4 μmol/L DHC) complexes in 683 
PBS (pH 7.4; λex = 295 nm, λem = 340 nm; data were corrected based on Eq. 1) (representative 684 
spectra and data) 685 
 686 
Fig. 4 Average CD spectra of native HSA (0.48 µmol/L) and (+)-DHC-HSA complex (each 687 
0.48 µmol/L) after 5-h incubation in 30 mmol/L phosphate buffer (pH 7.4; representative 688 
spectra) 689 
 690 
Fig. 5 a The first four docked DHC conformations (Ranks 1-4) on HSA. b Detailed 691 
presentation of Rank 4 DHC conformation surrounded by interacting amino acids of HSA 692 
 693 
Fig. 6 a Fluorescence intensity of DHC and HSA (2 and 4 µmol/L, respectively) in the 694 
presence of increasing concentrations of site marker (0-6 µmol/L) in PBS (pH 7.4; λex = 325 695 
nm, λem = 405 nm). b Fluorescence anisotropy values of ochratoxin A (1 µmol/L) in the 696 
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presence of HSA (1.5 µmol/L) and increasing concentrations of dihydrocitrinone (DHC), 697 
citrinin (CIT), and warfarin (WAR) (0-30 µmol/L each) in PBS (pH 7.4; λex = 393 nm, λem = 698 
446 nm). Data represent mean ± SEM (n = 3; * p < 0.05, ** p < 0.01) 699 
 700 
Fig. 7 Effects of DHC (a) and CIT (b) on the ATP levels of MDCK cells after 24-hr 701 
incubation, in the absence and presence of FBS (10%) or HSA (40 g/L) (compared to the 702 
control: ** p < 0.01; compared to the effect without albumin: # p < 0.05, ## p < 0.01). Data 703 
represent mean ± SEM (n = 3) 704 
  705 
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Tables 706 
 707 
Table 1 Decimal logarithmic values of Stern-Volmer quenching constants (KSV; unit: L/mol) 708 
and binding constants (K; unit: L/mol) of DHC-albumin complexes (see details in the 709 
“Spectroscopic measurements” section) Data represent mean ± SEM (n = 3) 710 
Complex 
logKSV (± SEM) 
(Eq. 2, λex = 295 nm) 
logK (±SEM) 
(Eqs. 3-7, λex = 295 nm) 
logK (±SEM) 
(Eqs. 3-7, λex = 325 nm) 
DHC-HSA 4.68 ± 0.07 4.89 ± 0.03 5.51 ± 0.05 
DHC-BSA 4.62 ± 0.07 4.75 ± 0.03 5.35 ± 0.02 
DHC-PSA 4.45 ± 0.03 4.65 ± 0.01 4.93 ± 0.04 
DHC-RSA 5.06 ± 0.00 5.30 ± 0.02 5.65 ± 0.02 
DHC dihydrocitrinone, HSA human serum albumin, BSA bovine serum albumin, PSA porcine 711 
serum albumin, RSA rat serum albumin 712 
 713 
Table 2 α-helix contents of HSA (0.48 µmol/L) and HSA after its incubation with (+)-DHC 714 
(both 0.48 µmol/L) in 30 mmol/L PBS (pH 7.4). α-helix percentage calculated with Eq. 10* 715 
and with the K2D3 software** (Louis-Jeune et al., 2012). Data represent mean ± SEM (n = 2)  716 
HSA + (+)-DHC 
(ratio) 
α-helix* 
(%) 
α-helix ** 
(%) 
relative difference 
HSA 73.3 ± 0.3 67.4 ± 0.2 
3-9% 
HSA + (+)-DHC (1:1) 66.7 ± 0.5 65.7 ± 0.3 
DHC dihydrocitrinone, CIT citrinin, HSA human serum albumin 717 
  718 
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